Printer Friendly

QUIDEL ACQUIRES MAJORITY IN EUROPEAN DISTRIBUTION COMPANY

 SAN DIEGO, Jan. 13 /PRNewswire/ -- QUIDEL Corp. (NASDAQ: QDEL) today announced the acquisition of the majority interest in its largest European fertility distributor, Tecnolab International B.V., which is headquartered in Alkmaar, the Netherlands. Details of the acquisition were not disclosed.
 Tecnolab currently distributes the QUIDEL fertility products together with other immunoassay and genetic probe diagnostic products to specialized fertility clinics, clinical labs and research labs. QUIDEL intends to relocate the management of its European business to the Netherlands to create a base for establishing distribution of its Conceive(TM) One-Step Ovulation and Pregnancy Tests to the home testing market in selected European countries.
 "Coupling this acquisition to the recently formed QUIDEL/Epignost Ventures in Austria formed last fall, will broaden our European presence and underscores our commitment to establish QUIDEL as a leading company in rapid diagnostic testing internationally," said Scott L. Glenn, QUIDEL chairman and chief executive officer. "We look forward to direct European sales to the Netherlands, Belgium and Luxembourg through Tecnolab which will complement our growing sales through our strategic distribution partners in other major European countries."
 QUIDEL Corp. develops, manufactures and markets rapid immunodiagnostic products that provide simple, accurate and cost- effective diagnoses in the areas of human fertility, infectious diseases, allergy and autoimmune disorders. These tests are designed for use in the physician's office, clinical laboratory and home testing markets.
 -0- 1/13/93
 /CONTACT: Scott L. Glenn, chairman and CEO, 619-552-7900, or Mark Francois, manager, investor relations, 619-552-7931, both of QUIDEL/
 (QDEL)


CO: QUIDEL Corp.; Tecnolab International B.V. ST: California IN: MTC SU: TNM

KJ-LS -- SD003 -- 4332 01/13/93 08:01 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 13, 1993
Words:271
Previous Article:NOVACARE'S SALE OF $175 MILLION OF CONVERTIBLE DEBENTURES DECLARED EFFECTIVE
Next Article:LARGEST MEETING OF CONVENTION CENTER USERS CHOOSES LOS ANGELES IN '96
Topics:


Related Articles
QUIDEL REPORTS FIRST QUARTER RESULTS
QUIDEL FINALIZES FRENCH ACQUISITION
QUIDEL ACQUIRES WORLDWIDE MARKETING RIGHTS FOR SAFEPLAN(TM) PRODUCT
QUIDEL REPORTS THIRD QUARTER RESULTS
QUIDEL ACQUIRES MAJORITY INTEREST IN SPAIN'S INMUNO ANALITICA S.L.
QUIDEL REPORTS FIRST QUARTER RESULTS
QUIDEL ACQUIRES PACIFIC BIOTECH INC. FROM ELI LILLY
QUIDEL REPORTS RECORD SALES FOR THE FOURTH QUARTER AND YEAR; QUIDEL BRANDED SALES FOR YEAR INCREASE 44 PERCENT
QUIDEL Corporation Signs Agreement to Acquire Metra Biosystems, Inc. in All Cash Transaction.
Quidel Corporation Completes Acquisition of Metra Biosystems; Quidel Expands Product Line Into Osteoporosis Diagnostics.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters